D-Index & Metrics Best Publications
Medicine
Italy
2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 121 Citations 72,049 1,300 World Ranking 1990 National Ranking 35

Research.com Recognitions

Awards & Achievements

2023 - Research.com Medicine in Italy Leader Award

Overview

What is she best known for?

The fields of study she is best known for:

  • Internal medicine
  • Cancer
  • Gene

Michele Baccarani mainly investigates Internal medicine, Myeloid leukemia, Imatinib mesylate, Imatinib and Immunology. Her studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Oncology. Her Myeloid leukemia research incorporates elements of Myeloid, Myelodysplastic syndromes, ABL and Phases of clinical research.

Her work deals with themes such as Survival rate, Tyrosine kinase, Alpha interferon and Young adult, which intersect with Imatinib mesylate. Her Imatinib research includes themes of Chronic myelogenous leukemia, Adverse effect, Philadelphia chromosome and Tyrosine-kinase inhibitor. Immunology is often connected to Neutropenia in her work.

Her most cited work include:

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (1271 citations)

What are the main themes of her work throughout her whole career to date?

Her primary areas of investigation include Internal medicine, Myeloid leukemia, Imatinib, Oncology and Immunology. Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. Her studies deal with areas such as Myeloid, Hematology and Leukemia as well as Myeloid leukemia.

Her Imatinib study combines topics from a wide range of disciplines, such as Discontinuation, Phases of clinical research, Adverse effect, Chronic myelogenous leukemia and Tyrosine-kinase inhibitor. Her Immunology research includes themes of Stem cell and Philadelphia chromosome. Her Nilotinib research integrates issues from Clinical trial and Pharmacology.

She most often published in these fields:

  • Internal medicine (53.50%)
  • Myeloid leukemia (28.07%)
  • Imatinib (24.57%)

What were the highlights of her more recent work (between 2013-2021)?

  • Internal medicine (53.50%)
  • Myeloid leukemia (28.07%)
  • Oncology (22.35%)

In recent papers she was focusing on the following fields of study:

Her scientific interests lie mostly in Internal medicine, Myeloid leukemia, Oncology, Imatinib and Nilotinib. Imatinib mesylate, Dasatinib, Adverse effect, Ponatinib and Hematology are the core of her Internal medicine study. Her Myeloid leukemia research incorporates elements of Tyrosine kinase and Leukemia.

Her Oncology research focuses on Transplantation and how it connects with Stem cell. The study incorporates disciplines such as Clinical trial, Surgery, Philadelphia chromosome and Tyrosine-kinase inhibitor in addition to Imatinib. Her work deals with themes such as Incidence, Cumulative incidence, Discontinuation, Bristol-Myers and Pediatrics, which intersect with Nilotinib.

Between 2013 and 2021, her most popular works were:

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (434 citations)
  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (379 citations)
  • Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) (298 citations)

In her most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Her primary areas of investigation include Internal medicine, Myeloid leukemia, Imatinib, Oncology and Imatinib mesylate. Her Surgery research extends to Internal medicine, which is thematically connected. The various areas that Michele Baccarani examines in her Myeloid leukemia study include Young adult, Hematology, Prospective cohort study and Chronic myelogenous leukemia, Leukemia.

Her Imatinib study contributes to a more complete understanding of Immunology. Her Oncology study which covers Long term survival that intersects with Disease risk, Treatment strategy, Disease remission, MEDLINE and Chromosome 22. Her studies deal with areas such as Tyrosine kinase, Cancer and Alpha interferon as well as Imatinib mesylate.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4398 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

4139 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2302 Citations

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes.
The New England Journal of Medicine (2010)

1825 Citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Blood (2006)

1772 Citations

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)

1754 Citations

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

JE Sokal;EB Cox;M Baccarani;S Tura.
Blood (1984)

1443 Citations

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci.
The Lancet (2010)

1121 Citations

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford.
Blood (2006)

1088 Citations

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)

1074 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michele Baccarani

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 496

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 475

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 250

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 207

Timothy P. Hughes

Timothy P. Hughes

South Australian Health and Medical Research Institute

Publications: 200

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 195

Michele Cavo

Michele Cavo

University of Bologna

Publications: 163

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 157

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 155

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 144

John M. Goldman

John M. Goldman

Imperial College London

Publications: 140

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 139

Jane F. Apperley

Jane F. Apperley

Imperial College London

Publications: 131

Brian J. Druker

Brian J. Druker

Oregon Health & Science University

Publications: 124

Pier Luigi Zinzani

Pier Luigi Zinzani

University of Bologna

Publications: 117

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 115

Trending Scientists

I. Ya. Aref'eva

I. Ya. Aref'eva

Steklov Mathematical Institute

Hong Hua

Hong Hua

University of Arizona

Hao Ling

Hao Ling

The University of Texas at Austin

Siegfried Schmauder

Siegfried Schmauder

University of Stuttgart

Joan M. Ogden

Joan M. Ogden

University of California, Davis

Richard W. Pastor

Richard W. Pastor

National Institutes of Health

Lun Pan

Lun Pan

Tianjin University

Lukas A. Mueller

Lukas A. Mueller

Boyce Thompson Institute

Maria Stefania Latrofa

Maria Stefania Latrofa

University of Bari Aldo Moro

Giampietro Ramponi

Giampietro Ramponi

University of Florence

Takuya Fujita

Takuya Fujita

Ritsumeikan University

Alistair M. Hetherington

Alistair M. Hetherington

University of Bristol

Eloy García-Calvo

Eloy García-Calvo

University of Alcalá

Marc J. Ruitenberg

Marc J. Ruitenberg

University of Queensland

Gerald L. Gottlieb

Gerald L. Gottlieb

Boston University

Jean-Pierre Pelletier

Jean-Pierre Pelletier

University of Montreal

Something went wrong. Please try again later.